Comparative Pharmacology
Head-to-head clinical analysis: HIPPURAN I 131 versus SODIUM IODIDE I 123.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIPPURAN I 131 versus SODIUM IODIDE I 123.
HIPPURAN I 131 vs SODIUM IODIDE I 123
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HIPPURAN I 131 (iodohippurate sodium I-131) is a radiopharmaceutical that is actively transported by the renal tubules, allowing dynamic imaging of renal function. The I-131 isotope emits beta and gamma radiation, enabling scintigraphic visualization of renal perfusion and excretion.
Sodium iodide I 123 is a radioactive isotope that emits gamma radiation. Following oral or intravenous administration, it is rapidly absorbed and selectively concentrated in the thyroid gland via the sodium-iodide symporter (NIS). The emitted gamma rays allow for imaging of thyroid tissue and detection of abnormal uptake patterns.
1 mCi (37 MBq) intravenously for adults; dose adjusted based on clinical indication and imaging protocol.
Oral: 400-800 μCi (14.8-29.6 MBq) for thyroid uptake studies; 150-300 μCi (5.6-11.1 MBq) for thyroid scan. Administer orally as a single dose.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged in renal impairment, up to 20-40 hours in severe impairment.
13.2 hours (physical T1/2); effective T1/2 ~13 hours in euthyroid; prolonged in hypothyroidism.
Renal: >95% excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Primarily renal (90%) as iodide; small amount feces (<5%) and negligible biliary.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical